Thus, it is likely that TM4SF5-expressing hepatocytes in chronic liver diseases including HCC may still utilize extracellular ALB for gain of function during earlier pathological stages with less hepatocyte damage or malignancy. Here, ALB is linked to hepatocellular carcinoma.